睿知中国疾病研究地图
候选清单0

上海上海交通大学医学院

上海交通大学医学院附属仁济医院

Renji Hospital

在本站收录的 53 种疾病中,这家医院列在其中 28 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

上海交通大学医学院附属仁济医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma2 篇牵头论文牵头 2 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma8 篇牵头论文牵头 1 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma104 篇牵头论文牵头 5 项开放试验
  4. 胃癌Stomach cancer65 篇牵头论文牵头 5 项开放试验
  5. 肝母细胞瘤Hepatoblastoma3 篇牵头论文
  6. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  7. 脊索瘤Chordoma1 篇牵头论文
  8. 骨肉瘤Osteosarcoma3 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour10 篇牵头论文
  10. 神经母细胞瘤Neuroblastoma2 篇牵头论文
  11. 多发性骨髓瘤Multiple myeloma24 篇牵头论文牵头 2 项开放试验
  12. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis3 篇牵头论文
  13. 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome1 篇牵头论文
  14. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder11 篇牵头论文牵头 1 项开放试验
  15. IgG4相关性疾病IgG4-related disease2 篇牵头论文
  16. 重症肌无力Myasthenia gravis3 篇牵头论文牵头 1 项开放试验
  17. 胆道闭锁Biliary atresia3 篇牵头论文
  18. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
  19. 大动脉炎Takayasu arteritis0 篇牵头论文
  20. 特发性肺纤维化Idiopathic pulmonary fibrosis0 篇牵头论文
  21. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis3 篇牵头论文
  22. 法布雷病Fabry disease1 篇牵头论文
  23. 杜氏肌营养不良Duchenne muscular dystrophy0 篇牵头论文
  24. 白塞病Behçet disease2 篇牵头论文
  25. IgA 肾病IgA nephropathy6 篇牵头论文
  26. 原发性胆汁性胆管炎Primary biliary cholangitis17 篇牵头论文牵头 1 项开放试验
  27. 原发性硬化性胆管炎Primary sclerosing cholangitis5 篇牵头论文
  28. 遗传性血管性水肿Hereditary angioedema2 篇牵头论文

未列出的收录疾病:尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、β 地中海贫血、血友病 A、血栓性血小板减少性紫癜、范可尼贫血、烟雾病、肝豆状核变性、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.08%。

牵头论文
2
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

上海有 10 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Trop2-targeted immunoPET Imaging of Solid Tumors
    分期
    II/III期
    开始
    2024-12
    登记号
    NCT06851663

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

  2. 正在招募
    CD70-targeted immunoPET Imaging of Malignant Cancers
    分期
    II期
    开始
    2024-12
    登记号
    NCT06852638

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与人工智能EB病毒与筛查
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。

牵头论文
8
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 4420222023: 0020232024: 2220242025: 002025

上海有 18 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC
    分期
    不分期
    开始
    2026-09
    登记号
    NCT07769866

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

  2. 正在招募
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    分期
    I期
    开始
    2024-07
    登记号
    NCT06465069

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京、广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题新辅助与综合治疗放疗免疫治疗
论文中的科室放疗科
牵头的论文8
  1. Amphiregulin and Epiregulin Confer Radioresistance in Esophageal Squamous Cell Carcinoma Through Oxidative Phosphorylation.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.2024Journal for immunotherapy of cancer免费全文
  3. FOXP3 expression in esophageal squamous cell carcinoma : Implications for cetuximab sensitivity and therapeutic strategies.2024Wiener klinische Wochenschrift
  4. Analysis of the Amine Submetabolome Using Novel Isotope-Coded Pyrylium Salt Derivatization and LC-MS: Herbs and Cancer Tissues as Cases.2022Analytical chemistry
  5. The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy.2022Frontiers in immunology免费全文
  6. Identifying key mutations of radioresponsive genes in esophageal squamous cell carcinoma.2022Frontiers in immunology免费全文
  7. Circular RNA hsa_circ_0003823 promotes the Tumor Progression, Metastasis and Apatinib Resistance of Esophageal Squamous Cell Carcinoma by miR-607/CRISP3 Axis.2022International journal of biological sciences免费全文
  8. Diffusion-weighted MRI and 18F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.2021Radiation oncology (London, England)免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC即将招募NCT07769866牵头方不分期2026-09 启动
  2. NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC进行中,不再招募NCT06762158牵头方不分期2024-10 启动
  3. Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer状态不明NCT04437212牵头方II期2020-07 启动
  4. Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of nCRT for Locally Advanced ESCC状态不明NCT04759235牵头方2020-01 启动
  5. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors正在招募NCT06465069研究中心I期2024-07 启动
  6. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma状态不明NCT02409186研究中心III期2015-03 启动
PubMed 以外找到的论文(未计入)6
  1. The feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): Update results of a retrospective exploratory study.2024Journal of Clinical Oncology会议摘要
  2. P-162 Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): A retrospective exploratory study2023Annals of Oncology会议摘要
  3. 70P A retrospective real-world study of anlotinib plus PD-1 inhibitors in advanced esophageal squamous cell carcinoma (ESCC) previously treated with immune checkpoint inhibitors (ICIs)2022Immuno-Oncology Technology论文
  4. APEC: Efficacy and toxicity of anlotinib plus PD-1 inhibitors as later-line therapy in advanced/metastatic esophageal squamous cell carcinoma (ESCC): A retrospective real-world study.2022Journal of Clinical Oncology会议摘要
  5. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncology会议摘要
  6. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 104 篇,占 0.7%。

牵头论文
104
2021–2025 年
牵头试验
17
任何状态,ClinicalTrials.gov
牵头的开放试验
5
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 262620212022: 121220222023: 252520232024: 232320242025: 17172025

上海有 15 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    FGF19 Overexpression Combination Unified Study in HCC-19
    分期
    II期
    开始
    2025-04
    登记号
    NCT06978933

    年龄 18 岁 至 未注明(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

  2. 正在招募
    DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
    分期
    IV期
    开始
    2024-10
    登记号
    NCT06353126

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

  3. 正在招募
    Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
    分期
    不分期
    开始
    2024-08
    登记号
    NCT06519578

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

  4. 正在招募
    GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
    分期
    不分期
    开始
    2023-01
    登记号
    NCT05926726

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

  5. 即将招募
    HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
    分期
    未注明
    开始
    2025-08
    登记号
    NCT07045558

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

  6. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物复发与预后影像、人工智能与早期发现
论文中的科室肿瘤内科影像/核医学科消化/肝病科普外/肝胆胰外科

这些论文过半是实验室或动物研究。

牵头的论文104
  1. Oridonin induces ferroptosis by inhibiting ubiquitin-mediated degradation of HMOX1 in hepatocellular carcinoma.2026Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  2. A therapeutic strategy integrating ultrasound-guided microwave ablation with nanocomposite hydrogels to enhance autophagy and suppress tumor growth in hepatocellular carcinoma.2025Acta biomaterialia
  3. Cardiorespiratory fitness-associated gene signature for prognosis in hepatocellular Carcinoma: Computational prediction and in vivo validation.2025Biochemical and biophysical research communications
  4. Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer.2025Cancer cell
  5. Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2-mediated increase of SOAT2 RNA methylation.2025Cancer communications (London, England)免费全文
  6. Therapeutic Potential of STE20-Type Kinase STK25 Inhibition for the Prevention and Treatment of Metabolically Induced Hepatocellular Carcinoma.2025Cellular and molecular gastroenterology and hepatology免费全文
  7. Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma.2025Cellular oncology (Dordrecht, Netherlands)免费全文
  8. PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinoma.2025Cellular oncology (Dordrecht, Netherlands)免费全文
  9. Role of immune cell homeostasis in research and treatment response in hepatocellular carcinoma.2025Clinical and experimental medicine免费全文
  10. Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation.2025Clinical and molecular hepatology免费全文
  11. DYRK1A-TGF-β signaling axis determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma.2025Developmental cell
  12. PRMT1-mediated modification of H4R3me2a promotes liver cancer progression by enhancing the transcriptional activity of SOX18.2025Hepatology communications免费全文
  13. Rescued with T and B lymphocytes depletion therapy for immune checkpoint inhibitor-associated transplant rejection.2025Immunotherapy免费全文
  14. Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma.2025Immunotherapy免费全文
  15. SNX17 mediates STAT3 activation to promote hepatocellular carcinoma progression via a retromer dependent mechanism.2025International journal of biological sciences免费全文
  16. Inhibition of liver cancer cell growth by metabolites S-adenosylmethionine and nicotinic acid originating from liver progenitor cells.2025Journal of gastroenterology免费全文
  17. The protection of UCK2 protein stability by GART maintains pyrimidine salvage synthesis for HCC growth under glucose limitation.2025Oncogene
  18. Hepatocellular carcinoma: signaling pathways and therapeutic advances.2025Signal transduction and targeted therapy免费全文
  19. GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma.2024Acta pharmacologica Sinica免费全文
  20. Upregulation of EFCAB7 after radiofrequency ablation promoting hepatocellular carcinoma metastasis and survival by regulating PARK7.2024Aging免费全文
  21. Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy.2024Cancer cell
  22. CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer.2024Cancer letters
  23. SSRI antidepressant citalopram reverses the Warburg effect to inhibit hepatocellular carcinoma by directly targeting GLUT1.2024Cell reports
  24. Lactate score classification of hepatocellular carcinoma helps identify patients with tumors that respond to immune checkpoint blockade therapy.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  25. TENT5A mediates the cancer-inhibiting effects of EGR1 by suppressing the protein stability of RPL35 in hepatocellular carcinoma.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  26. Macroscopic inhibition of DNA damage repair pathways by targeting AP-2α with LEI110 eradicates hepatocellular carcinoma.2024Communications biology免费全文
  27. DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma.2024Frontiers in immunology免费全文
  28. UBXN9 inhibits the RNA exosome function to promote T cell control of liver tumorigenesis.2024Hepatology (Baltimore, Md.)
  29. Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.2024Hepatology (Baltimore, Md.)
  30. NR4A3 inhibits the tumor progression of hepatocellular carcinoma by inducing cell cycle G0/G1 phase arrest and upregulation of CDKN2AIP expression.2024International journal of biological sciences免费全文
  31. Interleukin-25 as a Potential Biomarker in Lung Metastasis of Hepatocellular Carcinoma with HBV History in Chinese Patients: A Single Center, Case-control Study.2024International journal of medical sciences免费全文
  32. Protein O-fucosyltransferase 1 promotes PD-L1 stability to drive immune evasion and directs liver cancer to immunotherapy.2024Journal for immunotherapy of cancer免费全文
  33. PSMD9 promotes the malignant progression of hepatocellular carcinoma by interacting with c-Cbl to activate EGFR signaling and recycling.2024Journal of experimental & clinical cancer research : CR免费全文
  34. Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?2024Journal of hepatology
  35. UBXN1 promotes liver tumorigenesis by regulating mitochondrial homeostasis.2024Journal of translational medicine免费全文
  36. Transposable elements-mediated recruitment of KDM1A epigenetically silences HNF4A expression to promote hepatocellular carcinoma.2024Nature communications免费全文
  37. Zbtb7b defines a compensatory mechanism in MASLD-related HCC progression by suppressing H19-mediated hepatic lipid deposition.2024Physiological reports免费全文
  38. Identification and validation of a prognostic model based on four genes related to satellite nodules in hepatocellular carcinoma.2024Scientific reports免费全文
  39. Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial.2024Signal transduction and targeted therapy免费全文
  40. Akkermansia muciniphila might improve anti-PD-1 therapy against HCC by changing host bile acid metabolism.2024The journal of gene medicine
  41. GPX4 transcriptionally promotes liver cancer metastasis via GRHL3/PTEN/PI3K/AKT axis.2024Translational research : the journal of laboratory and clinical medicine
  42. A DNA/DMXAA/Metal-Organic Framework Activator of Innate Immunity for Boosting Anticancer Immunity.2023Advanced materials (Deerfield Beach, Fla.)
  43. Landscape of immunocytes infiltration and prognostic immune-related genes in hepatocellular carcinoma.2023Asian journal of surgery
  44. ScRNA-seq revealed targeting regulator of G protein signaling 1 to mediate regulatory T cells in Hepatocellular carcinoma.2023Cancer biomarkers : section A of Disease markers免费全文
  45. Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy.2023Cancer communications (London, England)免费全文
  46. Elevated nuclear PIGL disrupts the cMyc/BRD4 axis and improves PD-1 blockade therapy by dampening tumor immune evasion.2023Cellular & molecular immunology免费全文
  47. Effect of infiltrating immune cells in tumor microenvironment on metastasis of hepatocellular carcinoma.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  48. The negative effect of G1958A polymorphism on MTHFD1 protein stability and HCC growth.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  49. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.2023Clinical and translational medicine免费全文
  50. PET imaging of tumor vascular normalization in hepatocellular carcinoma.2023European journal of nuclear medicine and molecular imaging
  51. Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma.2023European journal of nuclear medicine and molecular imaging
  52. Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.2023Frontiers in immunology免费全文
  53. Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  54. Nucleolar HEAT Repeat Containing 1 Up-regulated by the Mechanistic Target of Rapamycin Complex 1 Signaling Promotes Hepatocellular Carcinoma Growth by Dominating Ribosome Biogenesis and Proteome Homeostasis.2023Gastroenterology
  55. Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis.2023Hepatology (Baltimore, Md.)
  56. Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention.2023Hepatology communications免费全文
  57. Syntaxin-6 promotes the progression of hepatocellular carcinoma and alters its sensitivity to chemotherapies by activating the USF2/LC3B axis.2023International journal of biological sciences免费全文
  58. Drug Repurposing Flubendazole to Suppress Tumorigenicity via PCSK9-dependent Inhibition and Potentiate Lenvatinib Therapy for Hepatocellular Carcinoma.2023International journal of biological sciences免费全文
  59. A negative feedback loop between KLF9 and the EMT program dictates metastasis of hepatocellular carcinoma.2023Journal of cellular and molecular medicine免费全文
  60. RIT1 regulates mitosis and promotes proliferation by interacting with SMC3 and PDS5 in hepatocellular carcinoma.2023Journal of experimental & clinical cancer research : CR免费全文
  61. hnRNPA2B1 promotes the occurrence and progression of hepatocellular carcinoma by downregulating PCK1 mRNA via a m6A RNA methylation manner.2023Journal of translational medicine免费全文
  62. CCBE1 promotes mitochondrial fusion by inhibiting the TGFβ-DRP1 axis to prevent the progression of hepatocellular carcinoma.2023Matrix biology : journal of the International Society for Matrix Biology
  63. AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway.2023Molecular carcinogenesis
  64. Evolving therapeutic landscape of advanced hepatocellular carcinoma.2023Nature reviews. Gastroenterology & hepatology
  65. STAT3 palmitoylation initiates a positive feedback loop that promotes the malignancy of hepatocellular carcinoma cells in mice.2023Science signaling免费全文
  66. Combating inconsistent evaluation of intra-tumor immune status by a novel transcriptomic signature in hepatocellular carcinoma.2023Signal transduction and targeted therapy免费全文
  67. Aggregation-Induced Emission (AIE) and Magnetic Resonance Imaging Characteristics for Targeted and Image-Guided siRNA Therapy of Hepatocellular Carcinoma.2022Advanced healthcare materials
  68. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.2022BMC cancer免费全文
  69. Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin.2022Biomolecules免费全文
  70. Sperm associated antigen 4 promotes SREBP1-mediated de novo lipogenesis via interaction with lamin A/C and contributes to tumor progression in hepatocellular carcinoma.2022Cancer letters
  71. ETV4 potentiates nuclear YAP retention and activities to enhance the progression of hepatocellular carcinoma.2022Cancer letters
  72. GPC3-targeted immunoPET imaging of hepatocellular carcinomas.2022European journal of nuclear medicine and molecular imaging
  73. Crucial role of T cells in NAFLD-related disease: A review and prospect.2022Frontiers in endocrinology免费全文
  74. Tissue-resident memory T cells in chronic liver diseases: Phenotype, development and function.2022Frontiers in immunology免费全文
  75. Multi-region sequencing with spatial information enables accurate heterogeneity estimation and risk stratification in liver cancer.2022Genome medicine免费全文
  76. A pre‑clinical model combining cryopreservation technique with precision‑cut slice culture method to assess the in vitro drug response of hepatocellular carcinoma.2022International journal of molecular medicine免费全文
  77. Tuftelin 1 Facilitates Hepatocellular Carcinoma Progression through Regulation of Lipogenesis and Focal Adhesion Maturation.2022Journal of immunology research免费全文
  78. STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1.2022Oncogene
  79. CaCO3 -Encapuslated Microspheres for Enhanced Transhepatic Arterial Embolization Treatment of Hepatocellular Carcinoma.2021Advanced healthcare materials
  80. Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen.2021Briefings in bioinformatics
  81. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology.2021Briefings in bioinformatics
  82. Deubiquitination of the repressor E2F6 by USP22 facilitates AKT activation and tumor growth in hepatocellular carcinoma.2021Cancer letters
  83. XRCC2 repairs mitochondrial DNA damage and fuels malignant behavior in hepatocellular carcinoma.2021Cancer letters
  84. NEIL3 Prevents Senescence in Hepatocellular Carcinoma by Repairing Oxidative Lesions at Telomeres during Mitosis.2021Cancer research免费全文
  85. A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-κB and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma.2021Cancer research
  86. MiR-103a promotes tumour growth and influences glucose metabolism in hepatocellular carcinoma.2021Cell death & disease免费全文
  87. Inhibition of AMPK activity by TRIM11 facilitates cell survival of hepatocellular carcinoma under metabolic stress.2021Clinical and translational medicine免费全文
  88. A cascade-network framework for integrated registration of liver DCE-MR images.2021Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
  89. Global DNA 5hmC and CK195hmC+ Contents: A Promising Biomarker for Predicting Prognosis in Small Hepatocellular Carcinoma.2021Current oncology (Toronto, Ont.)免费全文
  90. Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis.2021European journal of gastroenterology & hepatology
  91. Novel SREBP1 inhibitor cinobufotalin suppresses proliferation of hepatocellular carcinoma by targeting lipogenesis.2021European journal of pharmacology
  92. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.2021Frontiers in immunology免费全文
  93. Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.2021Genome medicine免费全文
  94. Microwave ablation for peribiliary hepatocellular carcinoma: propensity score analyses of long-term outcomes.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  95. The role of tumor-associated macrophages in primary hepatocellular carcinoma and its related targeting therapy.2021International journal of medical sciences免费全文
  96. Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma originating in the caudate lobe: A pilot clinical study.2021Journal of cancer research and therapeutics
  97. C-C chemokine hepatocellular carcinoma motif ligand 5-deficiency promotes hepatocellular carcinoma progression by affecting B cell recruitment.2021Journal of digestive diseases
  98. ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma.2021Journal of experimental & clinical cancer research : CR免费全文
  99. Metformin suppresses interleukin-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway.2021Journal of gastroenterology and hepatology
  100. Identification of the Different Gene Expression Characteristics from Liver Cirrhosis to Hepatocellular Carcinoma Using Single-Cell Sequencing Analyses.2021Journal of immunology research免费全文
  101. An antibody-free liver cancer screening approach based on nanoplasmonics biosensing chips via spectrum-based deep learning.2021NanoImpact
  102. EGFR activation limits the response of liver cancer to lenvatinib.2021Nature
  103. Exploring liver cancer biology through functional genetic screens.2021Nature reviews. Gastroenterology & hepatology
  104. Nuclear scaffold protein p54nrb/NONO facilitates the hypoxia-enhanced progression of hepatocellular carcinoma.2021Oncogene免费全文
中文论文(未计入)1
  1. [Strategies for immunotherapy-related hepatotoxicity in liver cancer].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)30
  1. FGF19 Overexpression Combination Unified Study in HCC-19正在招募NCT06978933牵头方II期2025-04 启动
  2. HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC即将招募NCT07045558牵头方2025-08 启动
  3. DEB-TACE Prior to Liver Transplantation in the Treatment of HCC正在招募NCT06353126牵头方IV期2024-10 启动
  4. Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma正在招募NCT06519578牵头方不分期2024-08 启动
  5. GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma正在招募NCT05926726牵头方不分期2023-01 启动
  6. Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC进行中,不再招募NCT06519721牵头方不分期2024-08 启动
  7. Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC已终止NCT05718882牵头方不分期2023-08 启动
  8. IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation状态不明NCT05339581牵头方不分期2022-05 启动
  9. Effects of Anesthetic Methods on Hepatic Cancer Cell Function in Vitro已完成NCT04510935牵头方不分期2020-08 启动
  10. Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )状态不明NCT04443322牵头方不分期2020-09 启动
  11. Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant状态不明NCT04425226牵头方不分期2020-08 启动
  12. Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma已完成NCT04642547牵头方不分期2020-12 启动
  13. Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence状态不明NCT04506398牵头方2020-09 启动
  14. Effects of Anesthetic Methods on Hepatic Cancer Cell Malignancy已完成NCT03594188牵头方不分期2018-07 启动
  15. CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma已完成NCT03146234牵头方不分期2017-03 启动
  16. Clinical and Basic Study for Pediatric Liver Transplantation状态不明NCT02503384牵头方2015-07 启动
  17. Anti-GPC3 CAR T for Treating Patients With Advanced HCC已完成NCT02395250牵头方I期2015-03 启动
  18. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  19. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)进行中,不再招募NCT05904886研究中心III期2023-09 启动
  20. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  21. A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab进行中,不再招募NCT04770896研究中心III期2021-04 启动
  22. IMC001 for Clinical Research on Advanced Digestive System Malignancies状态不明NCT05028933研究中心I期2021-09 启动
  23. A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation进行中,不再招募NCT04639180研究中心III期2021-04 启动
  24. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer已终止NCT04520906研究中心不分期2020-12 启动
  25. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  26. Chimeric Antigen Receptor T Cells Targeting Glypican-3已完成NCT03884751研究中心I期2019-08 启动
  27. NeuWave Microwave Ablation HCC China Study已完成NCT03783871研究中心不分期2019-02 启动
  28. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)已完成NCT03867084研究中心III期2019-05 启动
  29. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation状态不明NCT03356236研究中心2018-04 启动
  30. A Study of GPC3 Redirected Autologous T Cells for Advanced HCC状态不明NCT02715362研究中心I/II期2016-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 65 篇,占 0.7%。

牵头论文
65
2021–2025 年
牵头试验
26
任何状态,ClinicalTrials.gov
牵头的开放试验
5
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 181820212022: 7720222023: 8820232024: 131320242025: 19192025

上海有 18 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 12

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    ImmunoPET Imaging of Pancreatic Cancer
    分期
    不分期
    开始
    2024-11
    登记号
    NCT06602037

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

  2. 正在招募
    Target-specific immunoPET Imaging of Digestive System Carcinoma
    分期
    不分期
    开始
    2024-12
    登记号
    NCT06715839

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

  3. 正在招募
    The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
    分期
    不分期
    开始
    2023-12
    登记号
    NCT06081647

    年龄 18 岁 至 60 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院;另有 7 家列出的医院为研究中心上海、南京、南昌、杭州、济南

  4. 正在招募
    Atrophic Gastritis Predicts the Risk of Gastric Cancer
    分期
    未注明
    开始
    2023-12
    登记号
    NCT06203327

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

  5. 即将招募
    Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
    分期
    II期
    开始
    2024-08
    登记号
    NCT06531291

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

  6. 正在招募
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    分期
    不分期
    开始
    2026-06
    登记号
    NCT07552402

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南宁、成都、杭州、武汉、石家庄、福州、苏州、银川

  7. 正在招募
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    分期
    III期
    开始
    2025-05
    登记号
    NCT06901531

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、成都、杭州、武汉、石家庄、福州、郑州

  8. 正在招募
    Bovine Reinforcement in Stomach, Colorectal and Lung Operation
    分期
    III期
    开始
    2025-05
    登记号
    NCT06968221

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

  9. 正在招募
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    分期
    I期
    开始
    2025-07
    登记号
    NCT07066657

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、哈尔滨、杭州、武汉、郑州、重庆、长沙

  10. 正在招募
    Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
    分期
    III期
    开始
    2025-12
    登记号
    NCT07366528

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院;另有 3 家列出的医院为研究中心上海

  11. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、石家庄、福州、蚌埠、郑州、重庆、银川、长春、长沙、青岛

  12. 即将招募
    AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
    分期
    未注明
    开始
    2026-09
    登记号
    NCT07782294

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院;另有 2 家列出的医院为研究中心上海、安阳、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期早期发现与内镜影像与人工智能
论文中的科室消化/肝病科肿瘤内科影像/核医学科神经外科
牵头的论文65
  1. Bi-phase CT radiomics nomogram for the preoperative prediction of pylorus lymph node metastasis in non-pyloric gastric cancer patients.2025Abdominal radiology (New York)
  2. Long-term outcomes and quality of life of laparoscopic-assisted pylorus-preserving gastrectomy compared to laparoscopic-assisted distal gastrectomy with billroth I anastomosis for early gastric cancer(pT1N0M0): A Randomized Controlled Trial2025American journal of surgeryRCT
  3. Burden, trends, driving factors, and predictions of gastric cancer: a cross-national comparative analysis of China, Japan, and South Korea.2025BMC cancer免费全文
  4. Clinical study of adebrelimab in combination with apatinib and irinotecan for PD-1 inhibitor-ineffective advanced-stage gastric cancer: study protocol for a single-arm, single-centre, exploratory trial.2025BMJ open免费全文
  5. Metabolic fingerprinting enables rapid, label-free histopathology in gastric cancer diagnosis and prognostic prediction.2025Cell reports. Medicine免费全文
  6. Nuclear translocation of CDK5RAP3 regulated by NXF3 promotes the progression of gastric cancer.2025Cellular and molecular life sciences : CMLS免费全文
  7. Surufatinib plus paclitaxel as second-line therapy for advanced gastric cancer: a single-arm, phase 2 clinical trial.2025Cellular oncology (Dordrecht, Netherlands)免费全文
  8. High extracellular matrix stiffness upregulates TNNT1 to awaken dormant tumor cells in liver metastatic niches of gastric cancer.2025Cellular oncology (Dordrecht, Netherlands)免费全文
  9. CST1 promoted gastric cancer development by activating the AKT pathway.2025Clinics (Sao Paulo, Brazil)免费全文
  10. Automated interpretation of PD-L1 CPS based on multi-AI models integration strategy in gastric cancer.2025Frontiers in immunology免费全文
  11. Staging of operative link on gastritis assessment and operative link on gastric intestinal metaplasia systems for risk assessment of early gastric cancer: a case-control study.2025Journal of clinical pathology
  12. Clinicopathological Characteristics of Gastric Cancer in China: A 16-Year Single-Center Retrospective Clinical Study.2025Journal of digestive diseases
  13. A machine learning-enhanced gastric cancer diagnostic method based on shell-isolated nanoparticle-enhanced Raman spectroscopy.2025Nanoscale
  14. DEPP1: A prognostic biomarker linked to stroma‑rich and immunosuppressive microenvironment, promoting oxaliplatin resistance in gastric cancer.2025Oncology reports免费全文
  15. Renji endoscopic submucosal dissection video data set for early gastric cancer.2025Scientific data免费全文
  16. A Retrospective Study of Laparoscopic Distal Gastrectomy Guided by Carbon Nanoparticle Suspension Injection Lymphography for Gastric Cancer.2025The American surgeon
  17. Comprehensive exome profiling identifies ARHGEF12 mutation as a driver in gastric cancer with ovarian metastasis.2025Theranostics免费全文
  18. Effectiveness of circulating tumor cells and circulating tumor DNA in peritoneal lavage fluid for predicting metachronous peritoneal metastasis of gastric cancer.2025Translational research : the journal of laboratory and clinical medicine
  19. Total laparoscopy-assisted total gastrectomy with Da Vinci robotic system conducted by robotic enhanced neurocomputing joint intelligence gastrointestinal surgery hub (RENJI-GISH): a preliminary clinical study and case report.2025World journal of surgical oncology免费全文
  20. Comprehensive analysis of T-cell regulatory factors and tumor immune microenvironment in stomach adenocarcinoma.2024BMC cancer免费全文
  21. Effectiveness of peritoneal lavage fluid circulating tumour cells and circulating tumour DNA in the prediction of metachronous peritoneal metastasis of gastric cancer (pT4NxM0/pT1-3N+M0) after radical resection: protocol of a prospective si2024BMJ open免费全文
  22. Leveraging synthetic lethality to uncover potential therapeutic target in gastric cancer.2024Cancer gene therapy
  23. Circadian system disorder induced by aberrantly activated EFNB2-EPHB2 axis leads to facilitated liver metastasis in gastric cancer.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  24. Single-cell RNA transcriptomic analyses of tumor microenvironment of ovarian metastasis in gastric cancer.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  25. Serum Circulating mRNA Panel for the Early Detection of Gastric Cancer: A Potential Biomarker Test.2024ChemMedChem
  26. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers.2024European journal of nuclear medicine and molecular imaging
  27. [68Ga]Ga-FAPI-04 PET/MR imaging strategy in management of Krukenberg tumors (KTs) from gastric signet-ring-cell carcinoma: to overcome limitation of [68Ga]Ga-FAPI-04 PET imaging in KTs.2024European journal of nuclear medicine and molecular imaging
  28. Chromosomal copy number amplification-driven Linc01711 contributes to gastric cancer progression through histone modification-mediated reprogramming of cholesterol metabolism.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  29. Effectiveness and safety of Moluodan in the treatment of precancerous lesions of gastric cancer: A randomized clinical trial.2024Journal of digestive diseasesRCT
  30. Association of PD-1 + Treg/PD-1 + CD8 ratio and tertiary lymphoid structures with prognosis and response in advanced gastric cancer patients receiving preoperative treatment.2024Journal of translational medicine免费全文
  31. Targeting cellular senescence as a therapeutic vulnerability in gastric cancer.2024Life sciences
  32. DNA methyltransferase 3a-induced hypermethylation of the fructose-1,6-bisphosphatase-2 promoter contributes to gastric carcinogenesis.2024Molecular biology reports
  33. CCL19/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer.2023BMC cancer免费全文
  34. SIGLEC10+ macrophages drive gastric cancer progression by suppressing CD8+ T cell function.2023Cancer immunology, immunotherapy : CII免费全文
  35. Setd2 deficiency promotes gastric tumorigenesis through inhibiting the SIRT1/FOXO pathway.2023Cancer letters
  36. MAOA suppresses the growth of gastric cancer by interacting with NDRG1 and regulating the Warburg effect through the PI3K/AKT/mTOR pathway.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  37. The SLITRK4-CNPY3 axis promotes liver metastasis of gastric cancer by enhancing the endocytosis and recycling of TrkB in tumour cells.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  38. Tumor-associated macrophage-derived GDNF promotes gastric cancer liver metastasis via a GFRA1-modulated autophagy flux.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  39. Gastric metastasis from renal cell carcinoma 13 years after nephrectomy.2023Journal of digestive diseases
  40. First Total-Body Kinetic Modeling and Parametric Imaging of Dynamic 68Ga-FAPI-04 PET in Pancreatic and Gastric Cancer.2023Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  41. Clinical outcomes and potential therapies prediction of subgroups based on a ferroptosis-related long non-coding RNA signature for gastric cancer.2022Aging免费全文
  42. Delivery of LINC00589 via mesoporous silica nanoparticles inhibits peritoneal metastasis in gastric cancer.2022Cancer letters
  43. Fecal Signatures of Streptococcus anginosus and Streptococcus constellatus for Noninvasive Screening and Early Warning of Gastric Cancer.2022Gastroenterology
  44. Endoscopic, clinicopathological, and growth characteristics of minute gastric cancer.2022Journal of digestive diseases
  45. Synchronous in situ follicular neoplasia with MALT lymphoma and intramucosal adenocarcinoma in the stomach: A case report.2022Journal of digestive diseases
  46. Trends of stomach cancer survival: A systematic review of survival rates from population-based cancer registration.2022Journal of digestive diseases
  47. Neutrophil extracellular traps promote metastasis in gastric cancer patients with postoperative abdominal infectious complications.2022Nature communications免费全文
  48. Precise Targeting Therapy of Orthotopic Gastric Carcinoma by siRNA and Chemotherapeutic Drug Codelivered in pH-Sensitive Nano Platform.2021Advanced healthcare materials
  49. Plasmonic Alloys Reveal a Distinct Metabolic Phenotype of Early Gastric Cancer.2021Advanced materials (Deerfield Beach, Fla.)
  50. Tea Drinking and Risk of Cancer Incidence: A Meta-Analysis of Prospective Cohort Studies and Evidence Evaluation.2021Advances in nutrition (Bethesda, Md.)免费全文
  51. Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis.2021BMC cancer免费全文
  52. Age is the only predictor for upper gastrointestinal malignancy in Chinese patients with uncomplicated dyspepsia: a prospective investigation of endoscopic findings.2021BMC gastroenterology免费全文
  53. Stomach-specific c-Myc overexpression drives gastric adenoma in mice through AKT/mammalian target of rapamycin signaling.2021Bosnian journal of basic medical sciences免费全文
  54. CHPF promotes gastric cancer tumorigenesis through the activation of E2F1.2021Cell death & disease免费全文
  55. ZEB1-induced LINC01559 expedites cell proliferation, migration and EMT process in gastric cancer through recruiting IGF2BP2 to stabilize ZEB1 expression.2021Cell death & disease免费全文
  56. mTOR signaling regulates gastric epithelial progenitor homeostasis and gastric tumorigenesis via MEK1-ERKs and BMP-Smad1 pathways.2021Cell reports
  57. The Mechanism of Asparagine Endopeptidase in the Progression of Malignant Tumors: A Review.2021Cells免费全文
  58. Specific epigenetic age acceleration patterns among four molecular subtypes of gastric cancer and their prognostic value.2021Epigenomics
  59. Patterns of Lymph Node Metastasis in Patients With T1/T2 Gastroduodenal Neuroendocrine Neoplasms: Implications for Endoscopic Treatment.2021Frontiers in endocrinology免费全文
  60. Preservation of hepatic branch of the vagus nerve reduces the risk of gallstone formation after gastrectomy.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  61. Diagnostic endoscopic submucosal dissection in the diagnosis of biopsy-missed gastric mucosa-associated lymphoid tissue lymphoma.2021Journal of digestive diseases
  62. Norepinephrine Enhances Aerobic Glycolysis and May Act as a Predictive Factor for Immunotherapy in Gastric Cancer.2021Journal of immunology research免费全文
  63. Disruption of KDM4C-ALDH1A3 feed-forward loop inhibits stemness, tumorigenesis and chemoresistance of gastric cancer stem cells.2021Signal transduction and targeted therapy免费全文
  64. Poorly differentiated is more significant than signet ring cell component for lymph node metastasis in mixed-type early gastric cancer: a retrospective study from a large-volume hospital.2021Surgical endoscopy免费全文
  65. Sema3C promotes hepatic metastasis and predicts poor prognosis in gastric adenocarcinoma.2021The Journal of international medical research免费全文
中文论文(未计入)8
  1. [Long-term prognosis of surgical treatment for peri-gastric cardial gastrointestinal stromal tumors].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Thinking and strategy selection on the quality control of early gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Statistical analysis of disability-adjusted life years for stomach and colorectal cancers in Changning District of Shanghai].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  4. [Multiple primary malignancies combined with SWI/SNF complex-deficient gastric cancer: a case report and literature review].2023Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  5. [Influence of postoperative complications on prognosis of gastric cancer-The manifestation of gastric surgeon's skill, responsibility and empathy].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Current status and progression of minimally invasive surgery after neoadjuvant therapy for adenocarcinoma of esophagogastric junction].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Clinical significance of the deep learning algorithm based on contrast-enhanced CT in the differential diagnosis of gastric gastrointestinal stromal tumors with a diameter ≤ 5 cm].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Choice of function-preserving gastrectomy].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)43
  1. Target-specific immunoPET Imaging of Digestive System Carcinoma正在招募NCT06715839牵头方不分期2024-12 启动
  2. Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation即将招募NCT06531291牵头方II期2024-08 启动
  3. ImmunoPET Imaging of Pancreatic Cancer正在招募NCT06602037牵头方不分期2024-11 启动
  4. The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure正在招募NCT06081647牵头方不分期2023-12 启动
  5. A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer状态不明NCT05769725牵头方II期2023-03 启动
  6. Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer状态不明NCT05795296牵头方II期2022-12 启动
  7. Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.状态不明NCT05517408牵头方不分期2022-09 启动
  8. Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients已完成NCT05518929牵头方IV期2022-09 启动
  9. HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients状态不明NCT05526339牵头方不分期2022-09 启动
  10. HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk Patients状态不明NCT05510388牵头方不分期2022-09 启动
  11. Anxiety Before Non-cardiac Surgery in Adults状态不明NCT05596188牵头方2022-11 启动
  12. Nasal Mask Kit in Gastrointestinal Endoscopy已完成NCT05405530牵头方不分期2022-09 启动
  13. High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Sedated Gastrointestinal Endoscopes in Obesity状态不明NCT04500392牵头方不分期2021-05 启动
  14. Efficacy and Safety of Remimazolam Tosylate for Sedation in Gastroscopy状态不明NCT04727034牵头方不分期2021-03 启动
  15. Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients状态不明NCT05068180牵头方IV期2021-10 启动
  16. Safety and Feasibility of Reversible Induction Strategy状态不明NCT04434963牵头方2021-02 启动
  17. Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly Patients已完成NCT05030870牵头方不分期2021-09 启动
  18. A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer状态不明NCT04152889牵头方II期2020-04 启动
  19. Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach状态不明NCT05197933牵头方不分期2020-10 启动
  20. High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Gastroscopy Sedated by Propofol已完成NCT03332433牵头方不分期2017-11 启动
  21. Laparoscopy-assisted Pylorus-vagus Nerve Preserving Gastrectomy in the Treatment of Early Gastric Cancer状态不明NCT02936193牵头方不分期2017-08 启动
  22. WEI NASAL JET for The Sedation of Outpatient Upper Gastrointestinal Endoscopy状态不明NCT02436018牵头方不分期2015-03 启动
  23. Adverse Events During Upper Gastrointestinal Endoscopy状态不明NCT01979549牵头方2013-12 启动
  24. Atrophic Gastritis Predicts the Risk of Gastric Cancer正在招募NCT06203327牵头方(推断)2023-12 启动
  25. Correlation of Endoscopic Findings and Symptoms in Patients Undergoing the First Upper Gastrointestinal Endoscopy状态不明NCT03736824牵头方(推断)2018-01 启动
  26. Necessity Assessment of ME-NBI Targeted Biopsy Compared With EFB已完成NCT02738294牵头方(推断)不分期2013-06 启动
  27. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer正在招募NCT07552402研究中心不分期2026-06 启动
  28. AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis即将招募NCT07782294研究中心2026-09 启动
  29. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer正在招募NCT06901531研究中心III期2025-05 启动
  30. A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors正在招募NCT07066657研究中心I期2025-07 启动
  31. Bovine Reinforcement in Stomach, Colorectal and Lung Operation正在招募NCT06968221研究中心III期2025-05 启动
  32. Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer正在招募NCT07366528研究中心III期2025-12 启动
  33. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  34. IMC001 for Clinical Research on Advanced Digestive System Malignancies状态不明NCT05028933研究中心I期2021-09 启动
  35. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension已完成NCT04882241研究中心III期2020-07 启动
  36. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  37. Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC状态不明NCT04638959研究中心2019-09 启动
  38. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers状态不明NCT03468712研究中心不分期2018-03 启动
  39. Incidence of Pancreatic Fistula After Radical Gastrectomy状态不明NCT03391687研究中心2017-12 启动
  40. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)已终止NCT03019588研究中心III期2017-02 启动
  41. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer状态不明NCT02845986研究中心II期2016-09 启动
  42. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动
  43. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)状态不明NCT01609309研究中心III期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.9%。

牵头论文
3
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

上海有 8 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

上海有 11 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

上海有 15 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

上海有 60 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室放疗科
牵头的论文3
  1. Long-Circulating and Targeted Liposomes Co-loading Cisplatin and Mifamurtide: Formulation and Delivery in Osteosarcoma Cells.2024AAPS PharmSciTech
  2. Deciphering the role of lipid metabolism and acetylation in osteosarcoma: A comprehensive molecular analysis.2024Environmental toxicology
  3. Clinical significance of adjuvant therapy after radical surgery for primary osteosarcoma of the jaws.2023Wiener klinische Wochenschrift
早期论文(2016–2020 年)16
  1. Long noncoding RNA SNHG8 promotes the proliferation of osteosarcoma cells by downregulating miR-542-3p.2020Journal of biological regulators and homeostatic agents
  2. Polydatin induces apoptosis and autophagy via STAT3 signaling in human osteosarcoma MG-63 cells.2020Journal of natural medicines
  3. Organoid culture system for patient-derived lung metastatic osteosarcoma.2020Medical oncology (Northwood, London, England)
  4. MicroRNA-876-5p inhibits cell proliferation, migration and invasion by targeting c-Met in osteosarcoma.2019Journal of cellular and molecular medicine
  5. Long non-coding RNA HOXA-AS2 promotes migration and invasion by acting as a ceRNA of miR-520c-3p in osteosarcoma cells.2018Cell cycle (Georgetown, Tex.)
  6. SLIT2/ROBO1 axis contributes to the Warburg effect in osteosarcoma through activation of SRC/ERK/c-MYC/PFKFB2 pathway.2018Cell death & disease
  7. miR-149-5p inhibits cell growth by regulating TWEAK/Fn14/PI3K/AKT pathway and predicts favorable survival in human osteosarcoma.2018International journal of immunopathology and pharmacology
  8. MicroRNA-124 suppresses growth and aggressiveness of osteosarcoma and inhibits TGF-β-mediated AKT/GSK-3β/SNAIL-1 signaling.2018Molecular medicine reports
  9. Activation of TNF-α/NF-κB axis enhances CRL4BDCAF11 E3 ligase activity and regulates cell cycle progression in human osteosarcoma cells.2018Molecular oncology
  10. SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT-receptor complex.2018Oncogene
  11. Generating lung-metastatic osteosarcoma targeting aptamers for in vivo and clinical tissue imaging.2018Talanta
  12. Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma.2017Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  13. Long non-coding RNA XIST regulates PDCD4 expression by interacting with miR-21-5p and inhibits osteosarcoma cell growth and metastasis.2017International journal of oncology
  14. miR-92a promotes tumor growth of osteosarcoma by targeting PTEN/AKT signaling pathway.2017Oncology reports
  15. CRL4BDCAF11 E3 ligase targets p21 for degradation to control cell cycle progression in human osteosarcoma cells.2017Scientific reports
  16. MicroRNA-30a downregulation contributes to chemoresistance of osteosarcoma cells through activating Beclin-1-mediated autophagy.2016Oncology reports

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 1.9%。

牵头论文
10
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 5520242025: 222025

上海有 21 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科普外/肝胆胰外科消化/肝病科病理/检验科
牵头的论文10
  1. Development and validation of a machine-learning-based pathomics nomogram for predicting recurrence of localized primary gastrointestinal stromal tumors after complete surgical resection: A retrospective multicenter study.2025Cancer
  2. Aptamer-based drug delivery for targeted therapy of imatinib-resistant gastrointestinal stromal tumor.2025Theranostics
  3. Identification of D842V mutation in gastrointestinal stromal tumors based on CT radiomics: a multi-center study.2024Cancer imaging : the official publication of the International Cancer Imaging Society
  4. Drugs in the GIST Field (Therapeutic Targets and Clinical Trial Staging).2024Current drug delivery
  5. Prediction of high Ki-67 proliferation index of gastrointestinal stromal tumors based on CT at non-contrast-enhanced and different contrast-enhanced phases.2024European radiology
  6. Clinical importance of tumor rupture in gastrointestinal stromal tumor.2024Journal of digestive diseases
  7. Adult Female Patient with Untreated Truncus Arteriosus Type I and Torsion of Small Bowel Gastrointestinal Stromal Tumor: A Rare Case Report.2024The American journal of case reports
  8. Personalized radiomics signature to screen for KIT-11 mutation genotypes among patients with gastrointestinal stromal tumors: a retrospective multicenter study.2023Journal of translational medicine
  9. The nerve-tumour regulatory axis GDNF-GFRA1 promotes tumour dormancy, imatinib resistance and local recurrence of gastrointestinal stromal tumours by achieving autophagic flux.2022Cancer letters
  10. Low Distribution of TIM-3+ Cytotoxic Tumor-Infiltrating Lymphocytes Predicts Poor Outcomes in Gastrointestinal Stromal Tumors.2021Journal of immunology research
中文论文(未计入)7
  1. [Long-term prognosis of surgical treatment for peri-gastric cardial gastrointestinal stromal tumors].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Prognosis and its influencing factors in patients with non-gastric gastrointestinal stromal tumors at low risk of recurrence: a retrospective multicenter study in China].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Rethinking several issues related to surgical treatment for advanced GIST in the era of targeted therapy].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Identification and inner relation between gastrointestinal stromal tumor and intra-abdominal desmoid tumor].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with KIT/PDGFRA gene "homozygous mutation": a multicenter retrospective cohort study].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Clinical significance of the deep learning algorithm based on contrast-enhanced CT in the differential diagnosis of gastric gastrointestinal stromal tumors with a diameter ≤ 5 cm].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Act following etiquette and change with time: analysis and discussion on the difference between the current guidelines and clinical practice of gastrointestinal stromal tumor].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
早期论文(2016–2020 年)15
  1. Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors.2020Cancer medicine
  2. Clinicopathologic characteristics, diagnostic clues, and prognoses of patients with multiple sporadic gastrointestinal stromal tumors: a case series and review of the literature.2020Diagnostic pathology
  3. Recurrent Extra-gastrointestinal Stromal Tumor of the Vagina: A Case Report and Review of the Literature.2020Nigerian journal of clinical practice
  4. [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Updates and interpretations of the NCCN Clinical Practice Guidelines (2019 6th version) on gastrointestinal stromal tumor].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Pitfalls and dilemmas in the decision-making process of diagnosis and treatment on gastrointestinal stromal tumor].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. Aberrant accumulation of Dickkopf 4 promotes tumor progression via forming the immune suppressive microenvironment in gastrointestinal stromal tumor.2019Cancer medicine
  8. [Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Similarities and differences in diagnosis and treatment of gastrointestinal stromal tumors between China, Japan and Korea: from expert consensus to cooperation prospect].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  10. miR-182 controls cell growth in gastrointestinal stromal tumors by negatively regulating CYLD expression.2018Oncology reports
  11. miRNA-218-loaded carboxymethyl chitosan - Tocopherol nanoparticle to suppress the proliferation of gastrointestinal stromal tumor growth.2017Materials science & engineering. C, Materials for biological applications
  12. [Targeted therapy combined with immunotherapy in gastrointestinal stromal tumor: a new era of hope and challenges].2017Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  13. CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib.2016Scientific reports
  14. [Lancet in the era of targeted drug therapy: the role of surgery in the management of advanced gastrointestinal stromal tumor].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  15. [New challenges in the diagnosis and treatment of gastrointestinal stromal tumor: thinking and practice from evidence-based medicine to precision medicine].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy状态不明NCT05132738牵头方不分期2021-08 启动
  2. Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach状态不明NCT05197933牵头方不分期2020-10 启动
  3. Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor状态不明NCT02931981牵头方2016-10 启动
  4. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动
  5. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)正在招募NCT04924075研究中心II期2021-08 启动
  6. A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)已完成NCT04282980研究中心II期2020-04 启动
  7. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib已完成NCT04633122研究中心II期2020-11 启动
  8. A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor已完成NCT04254939研究中心I/II期2019-08 启动
  9. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST已完成NCT03465722研究中心III期2018-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

上海有 34 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 24 篇,占 1.4%。

牵头论文
24
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 7720222023: 7720232024: 3320242025: 552025

上海有 16 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
    分期
    不分期
    开始
    2024-10
    登记号
    NCT06594211

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

  2. 邀请入组
    Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
    分期
    未注明
    开始
    2026-11
    登记号
    NCT07833046

    年龄未注明(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

  3. 正在招募
    A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
    分期
    早期I期
    开始
    2026-04
    登记号
    NCT07493135

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

  4. 正在招募
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07555938

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南京、天津、广州、昆明、杭州、武汉、济南、温州、苏州、青岛

  5. 正在招募
    A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2026-09
    登记号
    NCT07760454

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、苏州

  6. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题联合用药复发与耐药诊断、微小残留病与危险分层
论文中的科室影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文24
  1. Lipin1-dependent transcriptional inactivation of SREBPs contributes to selinexor sensitivity in multiple myeloma.2025Acta pharmacologica Sinica免费全文
  2. Enhancer Extrachromosomal Circular DNA ANKRD28 Elicits Drug Resistance via POU2F2-Mediated Transcriptional Network in Multiple Myeloma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. First-line anti-BCMA CAR-T cell therapy in a fragile patient with biclonal gammopathy and giant plasma cell tumor multiple myeloma with multiple comorbidities: a case report.2025Frontiers in immunology免费全文
  4. Dual roles of IRE1α inhibition in reversing mitochondrial ROS-induced CD8+ T-cell senescence and exerting direct antitumor effects in multiple myeloma.2025Journal for immunotherapy of cancer免费全文
  5. Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor.2025Journal of translational medicine免费全文
  6. Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM).2024Cell communication and signaling : CCS免费全文
  7. The added diagnostic value of 18 F-FDG PET/CT radiomic analysis in multiple myeloma patients with negative visual analysis.2024Nuclear medicine communications
  8. From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy.2024Recent patents on anti-cancer drug discovery
  9. Integrating plasma proteomes with genome-wide association data for causal protein identification in multiple myeloma.2023BMC medicine免费全文
  10. Single-cell RNA sequencing reveals XBP1-SLC38A2 axis as a metabolic regulator in cytotoxic T lymphocytes in multiple myeloma.2023Cancer letters
  11. Distinct mechanisms of dysfunctional antigen-presenting DCs and monocytes by single-cell sequencing in multiple myeloma.2023Cancer science免费全文
  12. Metabolic kinetic modeling of [11C]methionine based on total-body PET in multiple myeloma.2023European journal of nuclear medicine and molecular imaging
  13. Unravelling the imbalanced Th17-like cell differentiation by single-cell RNA sequencing in multiple myeloma.2023International immunopharmacology
  14. C-reactive protein impairs immune response of CD8+ T cells via FcγRIIb-p38MAPK-ROS axis in multiple myeloma.2023Journal for immunotherapy of cancer免费全文
  15. Recombinant human p53 adenovirus injection combined with Bortezomib inhibits proliferation and promotes apoptosis in multiple myeloma.2023Leukemia research
  16. Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma.2022Acta pharmacologica Sinica免费全文
  17. Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma.2022BioMed research international免费全文
  18. Single-cell transcriptome profiling reveals the key role of ZNF683 in natural killer cell exhaustion in multiple myeloma.2022Clinical and translational medicine免费全文
  19. Promising therapeutic approaches for relapsed/refractory multiple myeloma.2022Hematology (Amsterdam, Netherlands)
  20. Causal relationships between inflammatory factors and multiple myeloma: A bidirectional Mendelian randomization study.2022International journal of cancer
  21. Annotating CD38 Expression in Multiple Myeloma with [18F]F-Nb1053.2022Molecular pharmaceutics
  22. Annotating BCMA Expression in Multiple Myelomas.2022Molecular pharmaceutics
  23. ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053.2021European journal of nuclear medicine and molecular imaging
  24. Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma.2021Military Medical Research免费全文
中文论文(未计入)3
  1. [Interpretation of diagnosis of multiple myeloma in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].2022Zhonghua nei ke za zhi
  2. [Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma].2022Zhonghua yi xue za zhi
  3. [Detection of minimal residual disease in patients with multiple myeloma:current status, challenges and prospective].2022Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
  1. Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection邀请入组NCT07833046牵头方2026-11 启动
  2. Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma即将招募NCT06594211牵头方不分期2024-10 启动
  3. Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.状态不明NCT05477797牵头方不分期2023-02 启动
  4. PVd Versus Vd in NDMM Patients With RI状态不明NCT05432414牵头方II期2022-12 启动
  5. A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma已完成NCT05620420牵头方2022-11 启动
  6. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma正在招募NCT07555938研究中心III期2026-06 启动
  7. A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma正在招募NCT07493135研究中心早期I期2026-04 启动
  8. A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma正在招募NCT07760454研究中心I/II期2026-09 启动
  9. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  10. Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma状态不明NCT05719701研究中心I/II期2023-03 启动
  11. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  12. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  13. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)已完成NCT03748953研究中心III期2019-01 启动
  14. Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients状态不明NCT03618602研究中心I期2018-04 启动
  15. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  16. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)已完成NCT02312258研究中心III期2015-04 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.8%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

上海有 5 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    分期
    III期
    开始
    2025-11
    登记号
    NCT07208058

    年龄 16 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、杭州、武汉、沈阳、石家庄、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题干细胞移植治疗方案诊断与预后
论文中的科室风湿免疫科消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

非典型溶血性尿毒症综合征

Atypical haemolytic uraemic syndrome

2021–2025 年中国大陆作者发表的 27 篇非典型溶血性尿毒症综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

上海有 2 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 11 篇,占 2.3%。

牵头论文
11
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 0020232024: 3320242025: 442025

上海有 4 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
    分期
    I期
    开始
    2024-03
    登记号
    NCT06249438

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断急性发作治疗影像
论文中的科室神经内科
牵头的论文11
  1. Influencing factors and clinical value of anti-aquaporin-4 antibody in cerebrospinal fluid: a study of 82 patients with neuromyelitis optica spectrum disorder.2025Acta neurologica Belgica
  2. Telitacicept Inhibits the Maturation and Differentiation of B Lymphocytes in NMOSD.2025Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
  3. Multi-tracer PET and MR imaging visualize distinct metabolic and inflammatory profiles in the white matter of NMOSD and MOGAD.2025Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics免费全文
  4. Efficacy of human umbilical cord mesenchymal stem cell in the treatment of neuromyelitis optica spectrum disorders: an animal study.2025Stem cell research & therapy免费全文
  5. Immunosuppressive therapy and COVID-19 infection in patients with NMOSD.2024Immunity, inflammation and disease免费全文
  6. Human NMO-IgG Induced Different Pathological and Immunological Changes in the CNS and Peripheral Tissues of Mice.2024Journal of integrative neuroscience
  7. Interactions Between Extracellular Vesicles and Autophagy in Neuroimmune Disorders.2024Neuroscience bulletin免费全文
  8. Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single-center, single-arm, open-label study.2022CNS neuroscience & therapeutics免费全文
  9. Enlarged perivascular spaces, neuroinflammation and neurological dysfunction in NMOSD patients.2022Frontiers in immunology免费全文
  10. Lymphocyte Subsets Are Associated with Disease Status in Neuromyelitis Optica Spectrum Disorders.2022Neuroimmunomodulation
  11. Low Frequency Ultrasound With Injection of NMO-IgG and Complement Produces Lesions Different From Experimental Autoimmune Encephalomyelitis Mice.2021Frontiers in immunology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy正在招募NCT06249438牵头方I期2024-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

上海有 4 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
    分期
    I/II期
    开始
    2026-01
    登记号
    NCT07061938

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、成都、武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题胰腺与胆管
论文中的科室消化/肝病科
牵头的论文2
  1. IgG4-related disease with duodenal bulb involvement.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  2. Interleukin-35 Promotes Th9 Cell Differentiation in IgG4-Related Disorders: Experimental Data and Review of the Literature.2021Clinical reviews in allergy & immunology
中文论文(未计入)1
  1. [Clinical characteristics and prognosis analysis of patients with IgG4-related hepatobiliary-pancreatic disease].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Multicenter Observational Study of PSC and IgG4-SC in China状态不明NCT05463445牵头方2022-07 启动
  2. Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease正在招募NCT07061938研究中心I/II期2026-01 启动
  3. A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease进行中,不再招募NCT05662241研究中心III期2023-01 启动
PubMed 以外找到的论文(未计入)1
  1. Case report of isolated gastric IgG4-related lesion and series of literature review2021Journal of Clinical Images and Medical Case Reports论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。

牵头论文
3
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025

上海有 7 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
    分期
    I期
    开始
    2024-03
    登记号
    NCT06249438

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题常规免疫治疗抗体与诊断孕期、儿童与老人
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

胆道闭锁

Biliary atresia

2021–2025 年中国大陆作者发表的 214 篇胆道闭锁 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.4%。

牵头论文
3
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 0020222023: 0020232024: 0020242025: 002025

上海有 3 家医院列在胆道闭锁下全国有 28 家医院列在胆道闭锁下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胆道闭锁开放试验。

这些数字背后的记录
研究主题肝移植长期结局

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

上海有 9 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 8 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Takayasu Arteritis Clinical Trial in China已完成NCT02981979研究中心不分期2016-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年没有牵头特发性肺纤维化的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 34 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
中文论文(未计入)1
  1. [Interstitial lung disease revisited].2021Zhonghua yi xue za zhi
早期论文(2016–2020 年)1
  1. Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways.2016Respirology (Carlton, Vic.)
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis即将招募NCT07131150研究中心II期2025-08 启动
  2. A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)已完成NCT06081621研究中心II期2023-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.4%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 1120242025: 002025

上海有 17 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文3
  1. Brain Delivery of Protein Therapeutics by Cell Matrix-Inspired Biomimetic Nanocarrier.2024Advanced materials (Deerfield Beach, Fla.)
  2. Rate-dependent depression is impaired in amyotrophic lateral sclerosis.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  3. SARS-CoV-2 impairs the disassembly of stress granules and promotes ALS-associated amyloid aggregation.2022Protein & cell
早期论文(2016–2020 年)2
  1. Increased activation ability of monocytes from ALS patients.2020Experimental neurology
  2. The nuclear localization sequence mediates hnRNPA1 amyloid fibril formation revealed by cryoEM structure.2020Nature communications

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

上海有 6 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年没有牵头杜氏肌营养不良的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 12 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Exosome-Derived Dystrophin from Allograft Myogenic Progenitors Improves Cardiac Function in Duchenne Muscular Dystrophic Mice.2018Journal of cardiovascular translational research

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

上海有 15 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室消化/肝病科风湿免疫科
牵头的论文2
  1. Esophageal Ulcer: Behçet's Disease or Tuberculosis?2024Digestive diseases and sciences
  2. Behcet's-like disease in a patient treated with Ixekizumab for chronic plaque psoriasis.2022Scandinavian journal of rheumatology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease已终止NCT04609397研究中心II期2020-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.8%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 1120222023: 0020232024: 2220242025: 002025

上海有 26 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
    分期
    III期
    开始
    2026-04
    登记号
    NCT07390123

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心Huangshan City、上海、临沂、北京、湛江、芜湖、西安、长春、长沙

  2. 正在招募
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    分期
    III期
    开始
    2025-07
    登记号
    NCT06963827

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科
牵头的论文6
  1. Urinary exosomal mRNAs as biomarkers for predicting the therapeutic effect of renin-angiotensin system inhibitors in IgA nephropathy patients.2024Clinica chimica acta; international journal of clinical chemistry
  2. Molecular characterization of m6A RNA methylation regulators with features of immune dysregulation in IgA nephropathy.2024Clinical and experimental medicine
  3. Downregulation of PPARα mediates FABP1 expression, contributing to IgA nephropathy by stimulating ferroptosis in human mesangial cells.2022International journal of biological sciences
  4. A single-cell survey of the human glomerulonephritis.2021Journal of cellular and molecular medicine
  5. KM55 Monoclonal Antibody Staining in IgA-Dominant Infection-Related Glomerulonephritis.2021Nephron
  6. Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial.2021Renal failureRCT
早期论文(2016–2020 年)3
  1. Serum miR-192 Is Related to Tubulointerstitial Lesion and Short-Term Disease Progression in IgA Nephropathy.2019Nephron
  2. Contrast-enhanced ultrasonography for assessment of tubular atrophy/interstitial fibrosis in immunoglobulin A nephropathy: a preliminary clinical study.2018Abdominal radiology (New York)
  3. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.2017Oncotarget
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN正在招募NCT07390123研究中心III期2026-04 启动
  2. A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy正在招募NCT06963827研究中心III期2025-07 启动
  3. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  4. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动
  5. Atrasentan in Patients With IgA Nephropathy进行中,不再招募NCT04573478研究中心III期2020-12 启动
  6. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动
  7. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 17 篇,占 5.7%。

牵头论文
17
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 4420222023: 3320232024: 6620242025: 332025

上海有 17 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Biochemical Response and Clinical Outcomes in Patients With PBC
    分期
    未注明
    开始
    2026-02
    登记号
    NCT07449793

    年龄 18 岁 至 85 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院上海

  2. 正在招募
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    分期
    III期
    开始
    2025-12
    登记号
    NCT07282353

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛

  3. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科
牵头的论文17
  1. The phenotypic and functional characteristics of intrahepatic CD69+CD103+ tissue-resident MAIT cells in primary biliary cholangitis.2025Journal of autoimmunity
  2. B cells drive CCR5+CD4+ tissue-resident memory T-cell cytotoxicity via IL-15Rα-IL-15 signaling in primary biliary cholangitis.2025Journal of hepatology
  3. Gut microbiome pattern impacts treatment response in primary biliary cholangitis.2025Med (New York, N.Y.)
  4. Osteoporosis and Primary Biliary Cholangitis: A Trans-ethnic Mendelian Randomization Analysis.2024Clinical reviews in allergy & immunology
  5. Gut Microbiota-Derived Butyrate Induces Epigenetic and Metabolic Reprogramming in Myeloid-Derived Suppressor Cells to Alleviate Primary Biliary Cholangitis.2024Gastroenterology
  6. Epidemiologic and genetic associations between primary biliary cholangitis and extrahepatic rheumatic diseases.2024Journal of autoimmunity
  7. Immunosuppression induces regression of fibrosis in primary biliary cholangitis with moderate-to-severe interface hepatitis.2024Journal of autoimmunity
  8. MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.2024Journal of gastroenterology
  9. Reply to: "ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort".2024Journal of hepatology
  10. Intestinal microbiota in biliary diseases.2023Current opinion in gastroenterology
  11. Implications of gut microbiota in autoimmune liver diseases.2023Minerva gastroenterology
  12. A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression.2023Nature communications
  13. Morphological, Functional, and Tissue Characterization of Silent Myocardial Involvement in Patients With Primary Biliary Cholangitis.2022Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  14. Immunologic Responses and the Pathophysiology of Primary Biliary Cholangitis.2022Clinics in liver disease
  15. NUDT1 promotes the accumulation and longevity of CD103+ TRM cells in primary biliary cholangitis.2022Journal of hepatology
  16. Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China.2022World journal of gastroenterology
  17. Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis.2021Gut microbes
中文论文(未计入)3
  1. [The immune-modulation therapy of autoimmune liver diseases].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  2. [Expression and clinical significance of interleukin-16 in patients with primary biliary cholangitis].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  3. [Liver: a unique immune organ].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
早期论文(2016–2020 年)17
  1. Epigenetics of Primary Biliary Cholangitis.2020Advances in experimental medicine and biology
  2. Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis.2020Clinical reviews in allergy & immunology
  3. Genome-wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis.2019Hepatology (Baltimore, Md.)
  4. Cytotoxic KLRG1 expressing lymphocytes invade portal tracts in primary biliary cholangitis.2019Journal of autoimmunity
  5. Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: Is alkaline phosphatase truly a surrogate marker?2019Journal of autoimmunity
  6. CTHRC1 expression in primary biliary cholangitis.2019Journal of digestive diseases
  7. [Clinicopathological analysis of anti-mitochondrial antibody negative primary biliary cholangitis-autoimmune hepatitis overlap syndrome].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  8. [Research advances of autoimmune liver diseases in 2018].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  9. Clinical analysis of liver transplantation in autoimmune liver diseases.2018Hepatobiliary & pancreatic diseases international : HBPD INT
  10. The immunobiology of mucosal-associated invariant T cell (MAIT) function in primary biliary cholangitis: Regulation by cholic acid-induced Interleukin-7.2018Journal of autoimmunity
  11. Editorial: scoring systems in primary biliary cholangitis - time to make a move. Authors' reply.2017Alimentary pharmacology & therapeutics
  12. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.2017Alimentary pharmacology & therapeutics
  13. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.2017Autoimmunity reviews
  14. [Advances in the treatment of primary biliary cholangitis].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  15. [Research advances in autoimmune liver diseases in 2016].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  16. The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis.2016Clinical reviews in allergy & immunology
  17. A Common Variant in CLDN14 is Associated with Primary Biliary Cirrhosis and Bone Mineral Density.2016Scientific reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Biochemical Response and Clinical Outcomes in Patients With PBC正在招募NCT07449793牵头方2026-02 启动
  2. The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching即将招募NCT07678645牵头方II期2026-06 启动
  3. Early Identification of Myocardial Impairment in PBC已完成NCT03545672牵头方2017-10 启动
  4. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA正在招募NCT07282353研究中心III期2025-12 启动
  5. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis正在招募NCT06051617研究中心III期2023-09 启动
  6. A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury已完成NCT06888115研究中心I期2025-03 启动
  7. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)进行中,不再招募NCT05896124研究中心II期2023-08 启动
  8. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis已完成NCT01857284研究中心III期2009-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 5 篇,占 5.0%。

牵头论文
5
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 3320232024: 1120242025: 002025

上海有 13 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    分期
    III期
    开始
    2026-05
    登记号
    NCT07387549

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、天津、广州、济南、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科
牵头的论文5
  1. Itaconate inhibits CD103 + T RM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.2024Hepatology (Baltimore, Md.)
  2. Intestinal microbiota in biliary diseases.2023Current opinion in gastroenterology
  3. P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.2023Hepatology (Baltimore, Md.)
  4. Implications of gut microbiota in autoimmune liver diseases.2023Minerva gastroenterology
  5. Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis.2022Gut
中文论文(未计入)2
  1. [Clinical characteristics and prognosis analysis of patients with IgG4-related hepatobiliary-pancreatic disease].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [The immune-modulation therapy of autoimmune liver diseases].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
早期论文(2016–2020 年)10
  1. CTHRC1 expression in primary biliary cholangitis.2019Journal of digestive diseases
  2. [Research advances of autoimmune liver diseases in 2018].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  3. Clinical analysis of liver transplantation in autoimmune liver diseases.2018Hepatobiliary & pancreatic diseases international : HBPD INT
  4. [Pathogenesis of immunoglobulin G4-related hepatobiliary disease].2018Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  5. [Clinical observation of isolated immunoglobulin G4-related sclerosing cholangitis and immunoglobulin G4 sclerosing cholangitis combined autoimmune pancreatitis].2018Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  6. [Research status and challenges in immunoglobulin G4-related hepatobiliary disease].2018Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  7. Editorial: scoring systems in primary biliary cholangitis - time to make a move. Authors' reply.2017Alimentary pharmacology & therapeutics
  8. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.2017Autoimmunity reviews
  9. Comparative clinical characteristics and natural history of three variants of sclerosing cholangitis: IgG4-related SC, PSC/AIH and PSC alone.2017Autoimmunity reviews
  10. [Research advances in autoimmune liver diseases in 2016].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching即将招募NCT07678645牵头方II期2026-06 启动
  2. Multicenter Observational Study of PSC and IgG4-SC in China状态不明NCT05463445牵头方2022-07 启动
  3. A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis正在招募NCT07387549研究中心III期2026-05 启动
  4. CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)进行中,不再招募NCT05896137研究中心II期2023-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性血管性水肿

Hereditary angioedema

2021–2025 年中国大陆作者发表的 32 篇遗传性血管性水肿 PubMed 英文论文中,这家医院牵头了 2 篇,占 6.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

上海有 2 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

上海交通大学医学院附属仁济医院

Renji Hospital

上海

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Ren Ji Hospital; RenJi Hospital; Shanghai Renji Hospital; Punan Branch of Renji Hospital; Chongqing University Renji Hospital; Renji Hospital of Shanghai Jiaotong University; Renji Hospital Affiliated; Punnan Branch of Renji Hospital

提出更正下载数据